tebipenem
Tebipenem is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Tebipenem is formulated as the ester tebipenem pivoxil due to the better absorption and improved bioavailability of this form. It has performed well in clinical trials for ear infection and looks likely to be further developed in future. It is only marketed in Japan. Tebipenem is the first carbapenem whose prodrug form, the pivalyl ester, is orally available. — Wikipedia
Clinical trial activity
14 trials · 13 clinical orgs · 0 marketing orgs
Earliest trial started Oct 20, 2017 (NCT03395249)
Timeline
Indications
Mechanism of action
- Penicillin-binding protein 1INHIBITOR
pbp1 inhibitor
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
SMILES
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@H]12- Mol. weight
- 497.64 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTebipenem ↗
- ChEMBLCHEMBL576981 ↗
- ChEMBLCHEMBL4297677 ↗
- ChEMBLCHEMBL2107486 ↗
Also known as
- orapenem
- tebipenem pivoxil
- tebipenem pivoxil
- tebipenem pivoxil
- tebipenem pivoxil
- tebipenem pivoxil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06727136 | Phase 1 | Nov 20, 2024 | GlaxoSmithKline, Spero Therapeutics |
| NCT06059846 | Phase 3 | Nov 30, 2023 | GlaxoSmithKline, Spero Therapeutics |
| NCT05856747 | Phase 1 | May 4, 2023 | Spero Therapeutics |
| NCT05121974 | Phase 2 | Dec 31, 2021 | GlaxoSmithKline, International Center for Diarrheal Disease Research, University of Washington |
| NCT04919954 | Phase 1 | Aug 31, 2021 | Spero Therapeutics, University of Connecticut |
| NCT04710407 | Phase 1 | Dec 7, 2020 | Clinartis, Pulmonary Associates, Phoenix, AZ, Spero Therapeutics |
| NCT04625855 | Phase 1 | Sep 30, 2020 | Covance, Spero Therapeutics |
| NCT04421885 | Phase 1 | Jun 1, 2020 | Spero Therapeutics |
| NCT04368585 | Phase 1 | May 31, 2020 | Spero Therapeutics |
| NCT04376554 | Phase 1 | Feb 10, 2020 | IQVIA, Karolinska Institute, Spero Therapeutics |
| NCT04238195 | Phase 1 | Jan 19, 2020 | Celerion, Spero Therapeutics |
| NCT04178577 | Phase 1 | Dec 31, 2019 | Spero Therapeutics |
| NCT03788967 | Phase 3 | Jun 3, 2019 | Spero Therapeutics |
| NCT03395249 | Phase 1 | Oct 20, 2017 | CPR Pharma Services Pty Ltd, Australia, Scientia Clinical Research Limited Sydney, Spero Therapeutics |
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spero Therapeutics | For profit | 13 | 12 | 2 | 2017 |
| GlaxoSmithKline | For profit | 3 | 0 | 3 | 2021 |
| Celerion | For profit | 1 | 0 | 1 | 2020 |
| Clinartis | For profit | 1 | 0 | 1 | 2020 |
| Covance | For profit | 1 | 0 | 1 | 2020 |
| CPR Pharma Services Pty Ltd, Australia | For profit | 1 | 0 | 1 | 2017 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 1 | 1 | 2021 |
| IQVIA | For profit | 1 | 0 | 1 | 2020 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Pulmonary Associates, Phoenix, AZ | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2017 |
| University of Connecticut | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2021 |